GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer

Endocrine-Related Cancer

Volumn 21, Issue 4, 2014, Pages

  Labrie, Fernand ^a  

^a NONE   (Canada)

Author keywords

Antiandrogens; Castration resistant prostate cancer; Combined androgen blockade; GnRH agonists; Inhibitors of steroidogenesis; Intracrinology

Indexed keywords

ABIRATERONE; ANDROGEN; ENZALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; LUTEINIZING HORMONE; PRASTERONE; PREDNISONE; STEROID 17ALPHA MONOOXYGENASE; ANTIANDROGEN; GONADORELIN;

ANDROGEN DEPRIVATION THERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; HUMAN; METASTASIS; MONOTHERAPY; NONHUMAN; PROSTATE CANCER; REVIEW; TREATMENT DURATION; AGONISTS; ANIMAL; CASTRATION; MALE; PROSTATIC NEOPLASMS;

ANDROGEN ANTAGONISTS; ANIMALS; CASTRATION; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84905988014     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0165     Document Type: Review

References (139)

1. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW & Scher HI 1999 Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. Journal of the National Cancer Institute 91 1869-1876.
2. Akaza H 2005 Effectiveness of Maximal Androgen Blockade (MAB): illusion or reality? Canadian Journal of Urology 12 (Suppl 1) 77-80.
3. Akaza H 2006 Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective. Cancer Science 97 243-247. (doi:10.1111/j.1349-7006.2006.00180.x)
4. Akaza H 2008 Current status and prospects of androgen depletion therapy for prostate cancer. Best Practice & Research. Clinical Endocrinology & Metabolism 22 293-302. (doi:10.1016/j.beem.2008.01.010)
5. Akaza H, Yamaguchi A, Matsuda T, Igawa M, Kumon H, Soeda A, Arai Y, Usami M, Naito S, Kanetake H et al. 2004 Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Japanese Journal of Clinical Oncology 34 20-28. (doi:10.1093/jjco/hyh001)
6. Akaza H, Hinotsu S, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Hirao Y, Murai M et al. 2006a The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. Journal of Urology 176 S47-S49. (doi:10.1016/j.juro.2006.06.070)
7. Akaza H, Homma Y, Usami M, Hirao Y, Tsushima T, Okada K, Yokoyama M, Ohashi Y & Aso Y 2006b Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU International 98 573-579. (doi:10.1111/j.1464-410X.2006.06349.x)
8. Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S & Hirao Y 2009 Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 115 3437-3445. (doi:10.1002/cncr.24395)
9. Amoss M, Burgus R, Blackwell R, Vale W, Fellows R & Guillemin R 1971 Purification, amino acid composition and N-terminus of the hypothalamic luteinizing hormone releasing factor (LRF) of ovine origin. Biochemical and Biophysical Research Communications 44 205-210.
10. Arai S, Miyashiro Y, Shibata Y, Tomaru Y, Kobayashi M, Honma S & Suzuki K 2011 Effect of castration monotherapy on the levels of adrenal androgens in cancerous prostatic tissues. Steroids 76 301-308. (doi:10.1016/j.steroids.2010.12.001)
11. Arnold JT, Le H, McFann KK & Blackman MR 2005 Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. American Journal of Physiology. Endocrinology and Metabolism 288 E573-E584. (doi:10.1152/ajpendo. 00454.2004)
12. Arnst C 2003 Developments to watch. Why did prostate cancer death rates fall? Business Week 92.
13. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E et al. 2008 Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Journal of Clinical Oncology 26 4563-4571. (doi:10.1200/JCO.2007.15.9749)
14. Auclair C, Kelly PA, Coy DH, Schally AV & Labrie F 1977a Potent inhibitory activity of [D-Leu6, des-Gly-NH210] ethylamide on LH/hCG and PRL testicular receptor levels in the rat. Endocrinology 101 1890-1893. (doi:10.1210/endo-101-6-1890)
15. Auclair C, Kelly PA, Labrie F, Coy DH & Schally AV 1977b Inhibition of testicular luteinizing receptor level by treatment with a potent luteinizing hormone-releasing hormone agonist of human chorionic gonadotropin. Biochemical and Biophysical Research Communications 76 855-862. (doi:10.1016/0006-291X(77) 91579-0)
16. Baker ME 2004 Co-evolution of steroidogenic and steroid-inactivating enzymes and adrenal and sex steroid receptors. Molecular and Cellular Endocrinology 215 55-62. (doi:10.1016/j.mce.2003.11.007)
17. Bélanger B, Bélanger A, Labrie F, Dupont A, Cusan L & Monfette G 1989 Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. Journal of Steroid Biochemistry 32 695-698. (doi:10.1016/0022-4731(89)90514-1)
18. Bélanger A, Pelletier G, Labrie F, Barbier O & Chouinard S 2003 Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. Trends in Endocrinology and Metabolism 14 473-479. (doi:10.1016/j.tem.2003.10. 005)
19. Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS & Ross SD 1999 Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer and Prostatic Diseases 2 4-8. (doi:10.1038/sj.pcan.4500265)
20. Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G et al. 2009 Duration of androgen suppression in the treatment of prostate cancer. New England Journal of Medicine 360 2516-2527. (doi:10.1056/NEJMoa0810095)
21. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L et al. 2010 Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376 1147-1154. (doi:10.1016/S0140-6736(10)61389-X)
22. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F et al. 2011 Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine 364 1995-2005. (doi:10.1056/NEJMoa1014618)
23. Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H et al. 2011 Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Research 71 6503-6513. (doi:10.1158/0008-5472.CAN-11-0532)
24. Caubet JF, Tosteson TD, Dong EW, Naylon EM, Whiting GW, Ernstoff MS & Ross SD 1997 Maximum androgen blockade in advanced prostate cancer: ameta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 49 71-78. (doi:10.1016/S0090-4295(96)00325-1)
25. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG & Sawyers CL 2004 Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 10 33-39. (doi:10.1038/nm972)
26. Collinson MP, Daniel F, Tyrrell CJ & Teasdale C 1993 Response of carcinoma of the prostate to withdrawal of flutamide. British Journal of Urology 72 662-663. (doi:10.1111/j.1464-410X.1993.tb16234.x)
27. Crawford ED 2009 Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology 73 S4-S10. (doi:10.1016/j. urology.2009.03.001)
28. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA & Goodman PJ 1989 A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New England Journal of Medicine 321 419-424. (doi:10.1056/NEJM198908173210702)
29. Denis LJ, Keuppens F, Smith PH, Whelan P, Carneiro de Moura JL, Newling D, Bono A & Sylvester R 1998 Maximal androgen blockade: final analysis of EORTC Phase III trial 30853. European Urology 33 144-151. (doi:10.1159/ 000019546)
30. Dillard PR, LinMF & Khan SA 2008 Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Molecular and Cellular Endocrinology 295 115-120. (doi:10.1016/j.mce.2008.08.013)
31. Dupont A, Labrie F, Giguere M, Borsanyi JP, Lacourciere Y, Bergeron N, Cusan L, Belanger A & Emond J 1988 Combination therapy with flutamide and [D-Trp6]LHRH ethylamide for stage C prostatic carcinoma. European Journal of Cancer & Clinical Oncology 24 659-666. (doi:10.1016/0277-5379(88)90296-9)
32. Dupont A, Cusan L, Gomez JL, Koutsilieris M, Suburu R, Emond J & Labrie F 1993a Combination therapy with flutamide and the LHRH agonist [D-Trp6-des-Gly-NH2]LHRH ethylamide in stage C prostatic carcinoma. British Journal of Urology 72 629-634. (doi:10.1111/j.1464-410X.1993.tb16223.x)
33. Dupont A, Gomez JL, Cusan L, Koutsilieris M & Labrie F 1993b Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. Journal of Urology 150 908-913. (Pubitemid 23241297)
34. Egawa M, Misaki T, Imao T, Yokoyama O, Fuse H, Suzuki K & Namiki M 2004 Retrospective study on stage B prostate cancer in the Hokuriku District, Japan. International Journal of Urology 11 304-309. (doi:10.1111/j.1442-2042. 2004.00797.x)
35. Eisenberger MA & Sinibaldi VW 2006 The role of cytotoxic chemotherapy in prostate cancer. A critical reevaluation 20 years later. Oncology 20 853-862 discussion 863, 867-868.
36. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM et al. 1998 Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. New England Journal of Medicine 339 1036-1042. (doi:10.1056/NEJM199810083391504)
37. El-Alfy M, Luu-The V, Huang XF, Berger L, Labrie F & Pelletier G 1999 Localization of type 5 17b-hydroxysteroid dehydrogenase, 3β-hydroxysteroid dehydrogenase and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology 140 1481-1491. (Pubitemid 29104255)
38. El Etreby MF, Habenicht UF, Louton T, Nishino Y & Schroder HG 1987 Effect of cyproterone acetate in comparison to flutamide and megestrol acetate on the ventral prostate, seminal vesicle and adrenal glands of adult male rats. Prostate 11 361-374. (doi:10.1002/pros.2990110408)
39. Evaul K, Li R, Papari-Zareei M, Auchus RJ & Sharifi N 2010 3β-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer. Endocrinology 151 3514-3520. (doi:10.1210/en.2010-0138)
40. Faure N, Labrie F, Lemay A, Bélanger A, Gourdeau Y, Laroche B & Robert G 1982 Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (GNRH) agonist in adult men. Fertility and Sterility 37 416-424. (Pubitemid 12183702)
41. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F et al. 2012 Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncology 13 983-992. (doi:10.1016/S1470-2045(12)70379-0)
42. Foster WR, Car BD, Shi H, Levesque PC, Obermeier MT, Gan J, Arezzo JC, Powlin SS, Dinchuk JE, Balog A et al. 2011 Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate 71 480-488. (doi:10.1002/pros.21263)
43. Fujimoto H, Nakanishi H, Miki T, Kubota Y, Takahashi S, Suzuki K, Kanayama HO, Mikami K & Homma Y 2011 Oncological outcomes of the prostate cancer patients registered in 2004: report from the Cancer Registration Committee of the JUA. International Journal of Urology 18 876-881. (doi:10.1111/j.1442-2042.2011.02895.x)
44. Furr BJ, Valcaccia B, Curry B, Woodburn JR, Chesterson G & Tucker H 1987 ICI176,334: a novel nonsteroidal peripherally selective antiandrogen. Journal of Endocrinology 113 R7-R9. (doi:10.1677/joe.0.113R007)
45. Garcia JA & Rini BI 2012 Castration-resistant prostate cancer: many treatments, many options, many challenges ahead. Cancer 118 2583-2593. (doi:10.1002/cncr.26582)
46. Hofland J, van Weerden WM, Dits NF, Steenbergen J, van Leenders GJ, Jenster G, Schroder FH & de Jong FH 2010 Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Research 70 1256-1264. (doi:10.1158/0008-5472.CAN-09-2092)
47. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P et al. 2004 Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. American Journal of Pathology 164 217-227. (doi:10.1016/S0002-9440(10)63112-4)
48. Homma Y, Akaza H, Okada K, Yokoyama M, Usami M, Hirao Y, Tsushima T, Sakamoto A, Ohashi Y & Aso Y 2004 Endocrine therapy with or without radical prostatectomy for T1b-T3N0M0 prostate cancer. International Journal of Urology 11 218-224. (doi:10.1111/j.1442-2042.2003.00781.x)
49. Huggins C & Hodges CV 1941 Studies of prostatic cancer. I. Effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research 1 293-297.
50. Isom-Batz G, Bianco FJ Jr, Kattan MW, Mulhall JP, Lilja H & Eastham JA 2005 Testosterone as a predictor of pathological stage in clinically localized prostate cancer. Journal of Urology 173 1935-1937. (doi:10.1097/01.ju.0000158040.33531.e7)
51. Jemal A, Bray F, Center MM, Ferlay J, Ward E & Forman D 2011 Global cancer statistics. CA: A Cancer Journal for Clinicians 61 69-90. (doi:10.3322/caac.20107)
52. Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, Leibenhaut MH, Husain SM, Rotman M, Souhami L et al. 2011 Radiotherapy and short-term androgen deprivation for localized prostate cancer. New England Journal of Medicine 365 107-118. (doi:10.1056/NEJMoa1012348)
53. Jung ME, Ouk S, Yoo D, Sawyers CL, Chen C, Tran C & Wongvipat J 2010 Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). Journal of Medicinal Chemistry 53 2779-2796. (doi:10.1021/jm901488g)
54. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB et al. 2010 Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New England Journal of Medicine 363 411-422. (doi:10.1056/NEJMoa1001294)
55. Karamanolakis D, Lambou T, Bogdanos J, Milathianakis C, Sourla A, Lembessis P, Halapas A, Pissimissis N, Dessypris N, Petridou ET et al. 2006 Serum testosterone: a potentially adjunct screening test for the assessment of the risk of prostate cancer among men with modestly elevated PSA values (> or =3.0 and <10.0 ng/ml). Anticancer Research 26 3159-3166. (Pubitemid 44161816)
56. Kelly WK & Scher HI 1993 Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. Journal of Urology 149 607-609. (Pubitemid 23094069)
57. van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, Boersma W & Trapman J 1991 Androgen receptors in endocrine-therapy-resistant human prostate cancer. International Journal of Cancer 48 189-193. (doi:10.1002/ijc.2910480206)
58. Labrie F 1991 Intracrinology. Molecular and Cellular Endocrinology 78 C113-C118. (doi:10.1016/0303-7207(91)90116-A)
59. Labrie F 2007 Multiple intracrine hormonal targets in the prostate: opportunities and challenges. BJU International 100 48-51. (doi:10.1111/j.1464- 410X.2007.06955.x)
60. Labrie F 2008 Endocrinology and the prostate. Preface. Best Practice & Research. Clinical Endocrinology & Metabolism 22 vii-vix. (doi:10.1016/j.beem.2008.02.005)
61. Labrie F 2010a DHEA after menopause - sole source of sex steroids and potential sex steroid deficiency treatment. Menopause Management 19 14-24.
62. Labrie F 2010b Hormonal therapy of prostate cancer. In Neuroendocrinology, The Normal Neuroendocrine System, Progress in Brain Research, pp 321-341. Eds L Martini, Chrousos GP, Labrie F, Pacak K & De Pfaff. Elsevier.
63. Labrie F 2011a Blockade of testicular and adrenal androgens in prostate cancer treatment. Nature Reviews. Urology 8 73-85. (doi:10.1038/nrurol.2010.231)
64. Labrie F 2011b Editorial: themajor role of androgens in prostate cancer and the need for more efficient blockade. Expert Review of Endocrinology & Metabolism 6 313-316. (doi:10.1586/eem.11.5)
65. Labrie F & Labrie C 2013 DHEA and intracrinology at menopause, a positive choice for evolution of the human species. Climacteric 16 205-213. (doi:10.3109/13697137.2012.733983)
66. Labrie F & Veilleux R 1986 A wide range of sensitivities to androgens develops in cloned Shionogi mouse mammary tumor cells. Prostate 8 293-300. (doi:10.1002/pros.2990080309)
67. Labrie F, Bélanger A, Cusan L, Séguin C, Pelletier G, Kelly PA, Reeves JJ, Lefebvre FA, Lemay A & Raynaud JP 1980 Antifertility effects of LHRH agonists in the male. Journal of Andrology 1 209-228.
68. Labrie F, Dupont A, Bélanger A, Cusan L, Lacourcière Y, Monfette G, Laberge JG, Emond J, Fazekas AT, Raynaud JP et al. 1982 New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clinical and Investigative Medicine 5 267-275. (Pubitemid 13217099)
69. Labrie F, Dupont A & Bélanger A 1985 Complete androgen blockade for the treatment of prostate cancer. In Important Advances in Oncology, pp 193-217. Eds VT de Vita, S Hellman & SA Rosenberg. Philadelphia: J.B. Lippincott.
70. Labrie C, Bélanger A & Labrie F 1988a Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology 123 1412-1417. (doi:10.1210/endo-123-3-1412)
71. Labrie F, Dupont A, Giguère M, Borsanyi JP, Lacourciere Y, Monfette G, Emond J & Bergeron N 1988b Benefits of combination therapy with flutamide in patients relapsing after castration. British Journal of Urology 61 341-346. (doi:10.1111/j.1464-410X.1988.tb13971.x)
72. Labrie C, Simard J, Zhao HF, Bélanger A, Pelletier G & Labrie F 1989 Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology 124 2745-2754. (doi:10.1210/endo-124-6-2745)
73. Labrie F, Dupont A, Cusan L, Gomez JL, Diamond P, Koutsilieris M, Suburu R, Fradet Y, Lemay M, Têtu B et al. 1993 Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clinical and Investigative Medicine 16 499-509. (Pubitemid 24111964)
74. Labrie F, Bélanger A, Cusan L, Simard J, Luu-The V, Labrie C, Gomez JL, Diamond P & Candas B 1996 History of LHRH agonists and combination therapy in prostate cancer. Endocrine-Related Cancer 3 243-278. (doi:10.1677/erc.0.0030243)
75. Labrie F, Candas B, Gomez JL & Cusan L 2002 Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? Urology 60 115-119. (doi:10.1016/S0090-4295(02)01639-4)
76. Labrie F, Bélanger A, Luu-The V, Labrie C, Simard J, Cusan L, Gomez JL & Candas B 2005 a Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocrine Reviews 26 361-379. (doi:10.1210/er. 2004-0017)
77. Labrie F, Luu-The V, Bélanger A, Lin S-X, Simard J& Labrie C 2005b Is DHEA a hormone? Starling review Journal of Endocrinology 187 169-196. (doi:10.1677/joe.1.06264)
78. Labrie F, Bélanger A, Bélanger P, Bérubé R, Martel C, Cusan L, Gomez JL, Candas B, Castiel I, Chaussade V et al. 2006 Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. Journal of Steroid Biochemistry and Molecular Biology 99 182-188. (doi:10.1016/j.jsbmb.2006.02.004)
79. Labrie F, Cusan L, Gomez JL, Martel C, Bérubé R, Bélanger P, Bélanger A, Vandenput L, Mellström D & Ohlsson C 2009 Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer. Journal of Steroid Biochemistry and Molecular Biology 113 52-56. (doi:10.1016/j.jsbmb.2008.11.004)
80. Labrie F, Martel C & Balser J 2011 Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary? Menopause 18 30-43. (doi:10.1097/gme.0b013e3181e195a6)
81. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR & Zakai N 2010 Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 121 833-840. (doi:10.1161/CIRCULATIONAHA.109.192695)
82. Lichtenberg F 2002 Measuring the health impacts of medical innovation and expenditure. In Health Services Research Seminal Series 2002-2003. University of Minnesota, Minneapolis, MN, USA.
83. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL & Visakorpi T 2001 Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Research 61 3550-3555. (Pubitemid 32694958)
84. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME & Nelson CC 2008 Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Research 68 6407-6415. (doi:10.1158/0008-5472.CAN-07-5997)
85. Locke JA, Nelson CC, Adomat HH, Hendy SC, Gleave ME & Guns ES 2009 Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts. Journal of Steroid Biochemistry and Molecular Biology 115 126-136. (doi:10.1016/j.jsbmb.2009.03.011)
86. Luu-The V 2011 Assessment of steroidogenic pathways that do not require testosterone as intermediate. Hormone Molecular Biology and Clinical Investigation 5 161-165. (doi:10.1515/HMBCI.2011.007)
87. Luu-The V, Bélanger A & Labrie F 2008 Androgen biosynthetic pathways in the human prostate. Best Practice & Research. Clinical Endocrinology & Metabolism 22 207-221. (doi:10.1016/j.beem.2008.01.008)
88. Massard C & Fizazi K 2011 Targeting continued androgen receptor signaling in prostate cancer. Clinical Cancer Research 17 3876-3883. (doi:10.1158/1078-0432.CCR-10-2815)
89. Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L et al. 2003 Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. Journal of Urology 169 1670-1675. (doi:10.1097/01.ju. 0000062674.43964.d0)
90. McNamara KM, Nakamura Y, Sasano H, Handelsman DJ & Simanainen U 2013 Prostate epithelial AR inactivation leads to increased intraprostatic androgen synthesis. Prostate 73 316-327. (doi:10.1002/pros.22570)
91. Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, Honma S, Keller ET & Namiki M 2004 The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Research 64 765-771. (doi:10.1158/0008-5472.CAN-03- 0130)
92. Mizokami A, Koh E, Izumi K, Narimoto K, Takeda M, Honma S, Dai J, Keller ET & Namiki M 2009 Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone. Endocrine-Related Cancer 16 1139-1155. (doi:10.1677/ERC-09-0070)
93. Mohler JL, Gregory CW, Ford OH III, Kim D, Weaver CM, Petrusz P, Wilson EM & French FS 2004 The androgen axis in recurrent prostate cancer. Clinical Cancer Research 10 440-448. (doi:10.1158/1078-0432.CCR-1146-03)
94. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD & Nelson PS 2008 Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Research 68 4447-4454. (doi:10.1158/0008-5472.CAN-08-0249)
95. Morgentaler A & Rhoden EL 2006 Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology 68 1263-1267. (doi:10.1016/j.urology.2006.08.1058)
96. Mostaghel EA & Plymate S 2011 New hormonal therapies for castration-resistant prostate cancer. Endocrinology and Metabolism Clinics of North America 40 625-642, x. (doi:10.1016/j.ecl.2011.05.013)
97. Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM et al. 2007 Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Research 67 5033-5041. (doi:10.1158/0008-5472.CAN-06-3332)
98. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS & Montgomery RB 2011 Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clinical Cancer Research 17 5913-5925.
99. Mostaghel EA, Solomon KR, Pelton K, Freeman MR & Montgomery RB 2012 Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS ONE 7 e30062. (doi:10.1371/journal.pone. 0030062)
100. Nakamura Y, Suzuki T, Nakabayashi M, Endoh M, Sakamoto K, Mikami Y, Moriya T, Ito A, Takahashi S, Yamada S et al. 2005 In situ androgen producing enzymes in human prostate cancer. Endocrine-Related Cancer 12 101-107. (doi:10.1677/erc.1.00914)
101. Namiki M, Kitagawa Y, Mizokami A & Koh E 2008 Primary combined androgen blockade in localized disease and its mechanism. Best Practice & Research. Clinical Endocrinology & Metabolism 22 303-315. (doi:10.1016/j.beem.2008.01.007)
102. Neri R, Monahan MD, Meyer JG, Afonso BA & Tabachnick IA 1967 Biological studies of an antiandrogen (SH-714). European Journal of Pharmacology 1 438-444. (doi:10.1016/0014-2999(67)90107-0)
103. Nishiyama T, Hashimoto Y & Takahashi K 2004 The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clinical Cancer Research 10 7121-7126. (doi:10.1158/1078-0432.CCR-04-0913)
104. Nishiyama T, Ikarashi T, Hashimoto Y, Suzuki K & Takahashi K 2006 Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score. Journal of Urology 176 1387-1391. (doi:10.1016/j.juro.2006.06.066)
105. Nishiyama T, Ikarashi T, Hashimoto Y, Wako K & Takahashi K 2007 The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score. Journal of Urology 178 1282-1288 discussion 1288-1289. (doi:10.1016/j.juro.2007.05.138)
106. Olsson M, Ekstrom L, Schulze J, Kjellman A, Akre O, Rane A & Gustafsson O 2010 Radical prostatectomy: influence on serum and urinary androgen levels. Prostate 70 200-205.
107. Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, Amory JK, Nelson PS, Matsumoto AM & Bremner WJ 2006 Persistent intraprostatic androgen concentrations after medical castration in healthy men. Journal of Clinical Endocrinology and Metabolism 91 3850-3856. (doi:10.1210/jc.2006-0968)
108. Pelletier G 2008 Expression of steroidogenic enzymes and sex-steroid receptors in human prostate. Best Practice & Research. Clinical Endocrinology & Metabolism 22 223-228. (doi:10.1016/j.beem.2008.02.004)
109. Pelletier G, Cusan L, Auclair C, Kelly PA, Désy L & Labrie F 1978 Inhibition of spermatogenesis in the rat by treatment with [D-Ala6, des-Gly-NH210]LHRH ethylamide. Endocrinology 103 641-643. (doi:10.1210/endo-103- 2-641)
110. Peto R & Dalesio O 2003 Breast and prostate cancer: 10-year survival gains in the hormonal adjuvant treatment trials. Abstract 328 presented at ECCO 12, Copenhagen, Denmark. European Journal of Cancer. Supplements 1 S101. (doi:10.1016/S1359-6349(03)90361-2)
111. Poortman J, Thijssen JH, von Landeghem AA, Wiegerinck MA & Alsbach GP1983 Subcellular distribution of androgens and oestrogens in target tissue. Journal of Steroid Biochemistry 19 939-945. (doi:10.1016/0022-4731(83)90037-7)
112. Prostate Cancer Triallists' Collaborative Group 2000 Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355 1491-1498. (doi:10.1016/S0140-6736(00)02163-2)
113. Rathkopf D & Scher HI 2013 Androgen receptor antagonists in castration-resistant prostate cancer. Cancer Journal 19 43-49. (doi:10.1097/PPO.0b013e318282635a)
114. Ribeiro M, Ruff P & Falkson G 1997 Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. American Journal of Clinical Oncology 20 605-608. (doi:10.1097/00000421-199712000-00015)
115. Rosner JM, Macome JC & Cardinali DP 1969 In vitro biosynthesis of sterols and steroids by rat submaxillary glands. Endocrinology 85 1000-1003. (doi:10.1210/endo-85-6-1000)
116. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S et al. 2013 Abiraterone in metastatic prostate cancer without previous chemotherapy. New England Journal of Medicine 368 138-148. (doi:10.1056/NEJMoa1209096)
117. Schally AV, Arimura A, Baba Y, Naur RM, Matsuo H, Redding TW, Debelijuk L & White WF 1971 Isolation and properties of FSH and LH-releasing hormone. Biochemical and Biophysical Research Communications 43 393-399.
118. Schatzl G, Madersbacher S, Thurridl T,Waldmuller J, Kramer G, Haitel A & Marberger M 2001 High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47 52-58. (doi:10.1002/pros.1046)
119. Scher HI & Sawyers CL 2005 Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. Journal of Clinical Oncology 23 8253-8261. (doi:10.1200/JCO.2005.03.4777)
120. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND et al. 2012 Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine 367 1187-1197. (doi:10.1056/NEJMoa1207506)
121. Sharifi N & Auchus RJ 2012 Steroid biosynthesis and prostate cancer. Steroids 77 719-726. (doi:10.1016/j.steroids.2012.03.015)
122. Sharkey DA & Fisher ER 1960 Carcinoma of the prostate in the absence of testicular tissue. Journal of Urology 83 468-470.
123. Shibata Y, Suzuki K, Arai S, Miyoshi Y, Umemoto S, Masumori N, Kamiya N, Ichikawa T, Kitagawa Y, Mizokami A et al. 2013 Impact of pre-treatment prostate tissue androgen content on the prediction of castration-resistant prostate cancer development in patients treated with primary androgen deprivation therapy. Andrology 1 505-511. (doi:10.1111/j.2047-2927.2013.00068.x)
124. Siegel R, Naishadham D & Jemal A 2013 Cancer statistics, 2013. CA: A Cancer Journal for Clinicians 63 11-30. (doi:10.3322/caac.21166)
125. Small EJ & Vogelzang NJ 1997 Second-line therapy for advanced prostate cancer: a shifting paradigm. Journal of Clinical Oncology 15 382-388. (Pubitemid 27021526)
126. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG & Balk SP 2006 Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Research 66 2815-2825. (doi:10.1158/0008-5472.CAN-05-4000)
127. St-Arnaud R, Lachance R, Kelly SJ, Belanger A, Dupont A & Labrie F 1986 Loss of luteinizing hormone bioactivity in patients with prostatic cancer treated with an LHRH agonist and a pure antiandrogen. Clinical Endocrinology 24 21-30. (doi:10.1111/j.1365-2265.1986.tb03250.x)
128. Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, Eymard JC, Falcon S, Calabro F, James N et al. 2009 Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. Journal of Clinical Oncology 27 5431-5438. (doi:10.1200/JCO. 2008.20.1228)
129. Suzuki H, Hinotsu S, Akaza H, Fujii Y, Kawakami S, Kihara K, Akakura K, Suzuki M, Kitamura T, Homma Y et al. 2010 Hormonal therapy for prostate cancer: current topics and future perspectives. International Journal of Urology 17 302-313. (doi:10.1111/j.1442-2042.2010.02460.x)
130. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I et al. 2004 Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine 351 1502-1512. (doi:10.1056/NEJMoa040720)
131. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ et al. 2003 Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. Journal of Clinical Oncology 21 2673-2678. (doi:10.1200/JCO.2003.11.102)
132. Titus MA, Schell MJ, Lih FB, Tomer KB & Mohler JL 2005 Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clinical Cancer Research 11 4653-4657. (doi:10.1158/1078-0432.CCR-05-0525)
133. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A et al. 2009 Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324 787-790. (doi:10.1126/science.1168175)
134. Twiddy AL, Leon CG & Wasan KM 2011 Cholesterol as a potential target for castration-resistant prostate cancer. Pharmaceutical Research 28 423-437. (doi:10.1007/s11095-010-0210-y)
135. Uemura M, Honma S, Chung S, Takata R, Furihata M, Nishimura K, Nonomura N, Nasu Y, Miki T, Shuin T et al. 2010 5αDH-DOC (5α-dihydro- deoxycorticosterone) activates androgen receptor in castration-resistant prostate cancer. Cancer Science 101 1897-1904. (doi:10.1111/j.1349-7006.2010. 01620.x)
136. Ueno S, Namiki M, Fukagai T, Ehara H, Usami M & Akaza H 2006 Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study. International Journal of Urology 13 1494-1500. (doi:10.1111/j.1442-2042.2006.01604.x)
137. Voutilainen R & Miller WL 1986 Developmental expression of genes for the stereoidogenic enzymes P450scc (20,22-desmolase), P450c17 (17α-hydroxylase/17,20-lyase), and P450c21 (21-hydroxylase) in the human fetus. Journal of Clinical Endocrinology and Metabolism 63 1145-1150. (doi:10.1210/jcem-63-5-1145)
138. Yoon FH, Gardner SL, Danjoux C, Morton G, Cheung P & Choo R 2008 Testosterone recovery after prolonged androgen suppression in patients with prostate cancer. Journal of Urology 180 1438-1443 discussion 1443-1444. (doi:10.1016/j.juro.2008.06.029)
139. Yuan X & Balk SP 2009 Mechanisms mediating androgen receptor reactivation after castration. Urologic Oncology 27 36-41. (doi:10.1016/j. urolonc.2008.03.021)